Key result
Patients with thyrotoxic periodic paralysis who developed paradoxical hypokalemia required significantly more intravenous KCl to recover (104 vs 48 mmol, P<0.001) and had more severe rebound hyperkalemia.
Absolute Event Rate: 104% vs 48%
p-value: p=<0.001
In patients with thyrotoxic periodic paralysis, those who develop paradoxical hypokalemia during KCl treatment require higher doses for recovery and are at greater risk for severe rebound hyperkalemia.
No takes yet. Share an insight, caveat, or question.
May warrant cautious KCl repletion and rebound monitoring; hypothesis-generating for tailored protocols pending prospective trials.
Shiang et al. (2009) studied Thyrotoxic periodic paralysis (TPP) (n=78). Intravenous KCl was evaluated on Dose of KCl administered to restore muscle strength (paradoxical hypokalemia vs no paradoxical hypokalemia) (p=<0.001). Patients with thyrotoxic periodic paralysis who developed paradoxical hypokalemia required significantly more intravenous KCl to recover (104 vs 48 mmol, P<0.001) and had more severe rebound hyperkalemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: